Generation and characterization of a live, bivalent vaccine against human immunodeficiency virus and Ebola virus

Loading...
Thumbnail Image
Date
2016
Authors
Mendoza, Emelissa J.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Human immunodeficiency virus (HIV) causes acquired immunodeficiency syndrome by targeting and destroying CD4+ T cells via its Envelope protein (Env), while Ebola virus (EBOV) causes a lethal hemorrhagic fever and targets antigen presenting cells (APCs) via its glycoprotein (GP). There are no licensed vaccines for either virus, posing a problem particularly in Africa, where succumbing to EBOV or HIV is a grim reality. We hypothesized that a replication-competent HIV expressing GP as a replacement for Env will redirect the virus from CD4+ T cells toward antigen presenting cells and act as a live, bivalent vaccine to induce cellular and humoral immune responses against both pathogens, and confer protection against a lethal EBOV challenge in mice. Recombinant HIV-1 molecular clones containing different truncations of the GP gene to replace HIV gp120 were generated and used to rescue three GP-expressing vaccines, HIV-EBOV, HIV-EBOVΔ1, and HIV-EBOVΔ2. These demonstrated tropism for the monocyte cell line, THP-1, and decreased tropism for the CD4+ T cell line, SupT1. While all vaccines induced HIV p24- and GP-specific IFN-γ-secreting T cell responses, HIV-EBOVΔ1 and HIV-EBOVΔ2 induced the most robust responses at 21 days post-vaccination (dpv), respectively. While all vaccines induced total anti-p24 and anti-GP IgG responses, HIV-EBOVΔ1 induced the most robust responses at 42 dpv. HIV-EBOVΔ1 demonstrated the highest protective efficacy against lethal EBOV challenge, followed by HIV-EBOVΔ2 and HIV-EBOV, providing 83%, 67%, and 50% survival in mice, respectively. HIV-EBOVΔ1 shows promise as a protective vaccine against EBOV, but may require further optimization and characterization regarding its mechanism of action and ability to protect against HIV.
Description
Keywords
Vaccine, HIV, Ebola virus, Immunology
Citation